Anterior Uveitis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers Global Anterior Uveitis Treatment Market Size and it is Segmented by Treatment Type (Corticosteroids, Cycloplegic Agents, Anti-TNF Agents, and Immunosuppressants), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Anterior Uveitis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Anterior Uveitis Treatment Market Size

Anterior Uveitis Treatment Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 5.80 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Anterior Uveitis Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Anterior Uveitis Treatment Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Anterior Uveitis Treatment Market Analysis

The Global Anterior Uveitis Treatment Market is expected to register a CAGR of 5.8% during the forecast period.

The COVID-19 pandemic has disrupted healthcare patterns, as missed visits have led to the potential for significant disease progression in some patients with noninfectious uveitis. Uveitis patients may be at higher risk than the general population of contracting COVID-19 or suffering a more severe course of the virus. As per the article published in March 2021 by the National Library of Medicine, there was an 86% reduction in outpatient treatment for uveitis in spring 2020 compared to the same period in 2019, thereby affecting the market significantly. However, with the increase in vaccination programs, the outpatient departments started operating at full capacity and are expected to grow during the study period. Furthermore, market growth is stabilizing in the current scenario following COVID-19 as global restrictions ease and disease screening services resume.

There has been an increasing prevalence of uveitis across the globe, leading to blindness. An article published in the journal Frontiers in Medicine in September 2021 indicated that non-infectious uveitis is a leading cause of vision loss around the world. The article indicated that the estimated prevalence of non-infectious uveitis in the United States is 121 per 100,000 people every year. Uveitis is a sight-threatening inflammatory disease affecting the uveal layer of the eye. Redness of the eyes, blurring of the vision, the small size of the pupil, and sensitivity to light can be possible symptoms of anterior uveitis, which, if not treated, can result in permanent blindness. As a result, there are ongoing developments in product applications and treatment modalities.

New treatment options for uveitis, such as corticosteroids and anti-inflammatory drugs, are already gaining traction in the market. The growing number of product launches and rising research and development studies are expected to boost market growth. For instance, in May 2021, Oculis S.A. reported positive data from two clinical proof-of-concept Phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in Dry Eye Disease (DED) and Acute Anterior Uveitis (AAU). With such good results from the studies, the approval process is likely to be easier, which will help the market.

Furthermore, in August 2021, Cipla received final approval from the United States Food and Drug Administration for its abbreviated new drug application for difluprednate ophthalmic emulsion 0.05%. Difluprednate ophthalmic emulsion 0.05% is the generic version of Novartis's Durezol and is used for the treatment of inflammation and pain associated with ocular surgery as well as for the treatment of endogenous anterior uveitis. So, more product approvals meet the growing demand for treatments for anterior uveitis, which boosts the market.

In addition, other factors, such as the growing geriatric population, are also expected to be driving factors in the growth of the market. However, the high cost of medications and the side effects of corticosteroid treatment are expected to stymie market growth.

Anterior Uveitis Treatment Industry Overview

The Anterior Uveitis Treatment Market is consolidated and moderately competitive. There has been a presence of a considerable number of companies that are increasingly adopting strategic initiatives such as new product development, mergers and acquisitions, and regional expansion. Major players in the market include Novartis AG, AbbVie Inc., Aciont Inc., Tarsier Pharma Ltd., and Amgen, among others.

Anterior Uveitis Treatment Market Leaders

  1. Novartis AG

  2. AbbVie Inc.

  3. Aciont Inc.

  4. Amgen

  5. Tarsier Pharma Ltd

  6. *Disclaimer: Major Players sorted in no particular order
Anterior Uveitis Treatment Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Anterior Uveitis Treatment Market News

  • March 2022: Bausch + Lomb and Clearside Biomedical launched Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with anterior, intermediate, posterior, or pan uveitis in the United States.
  • January 2022: Tarsier Pharma, an advanced clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for blinding ocular diseases, launched an education website about the disease uveitic glaucoma at www.uveiticglaucoma.com as a service to the public.

Anterior Uveitis Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Cases of the Uveitis
    • 4.2.2 Development of Novel Drugs and Treatments
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated with the Medications
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Treatment Type
    • 5.1.1 Corticosteroids
    • 5.1.2 Cycloplegic Agents
    • 5.1.3 Anti-TNF Agents
    • 5.1.4 Immunosuppressants
  • 5.2 By Distribution Channel
    • 5.2.1 Hospitals Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Aldeyra Therapeutics, Inc.
    • 6.1.3 Amgen
    • 6.1.4 Clearside Biomedical, Inc.
    • 6.1.5 Novartis AG
    • 6.1.6 Aciont Inc.
    • 6.1.7 Bausch & Lomb Incorporated
    • 6.1.8 Sirion Therapeutics, Inc.
    • 6.1.9 Santen Inc.
    • 6.1.10 Tarsier Pharma Ltd.
    • 6.1.11 Oculis
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Anterior Uveitis Treatment Industry Segmentation

As per the scope of the report, anterior uveitis is an eye inflammation that involves the middle layer of the eye. Anterior uveitis is the most common form of uveitis and is the most frequent extra-articular manifestation of ankylosing spondylitis (AS) patients. Untreated anterior uveitis results in loss of vision and permanent eye damage that arises with the development of infections such as glaucoma, retinal edema, or cataract. Anterior uveitis can be treated with eye drops containing anti-inflammatory drugs. The Anterior Uveitis Treatment Market is Segmented by Treatment Type (Corticosteroids, Cycloplegic Agents, Anti-TNF Agents, and Immunosuppressants), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment Type Corticosteroids
Cycloplegic Agents
Anti-TNF Agents
Immunosuppressants
By Distribution Channel Hospitals Pharmacies
Retail Pharmacies
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Anterior Uveitis Treatment Market Research FAQs

What is the current Global Anterior Uveitis Treatment Market size?

The Global Anterior Uveitis Treatment Market is projected to register a CAGR of 5.8% during the forecast period (2025-2030)

Who are the key players in Global Anterior Uveitis Treatment Market?

Novartis AG, AbbVie Inc., Aciont Inc., Amgen and Tarsier Pharma Ltd are the major companies operating in the Global Anterior Uveitis Treatment Market.

Which is the fastest growing region in Global Anterior Uveitis Treatment Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Anterior Uveitis Treatment Market?

In 2025, the North America accounts for the largest market share in Global Anterior Uveitis Treatment Market.

What years does this Global Anterior Uveitis Treatment Market cover?

The report covers the Global Anterior Uveitis Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Anterior Uveitis Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Anterior Uveitis Treatment Industry Report

Statistics for the 2025 Global Anterior Uveitis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Anterior Uveitis Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.